A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)

NCT07227597 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

170

Enrollment

INDUSTRY

Sponsor class

Conditions

Small Cell Lung Cancer Extensive Stage

Interventions

DRUG: Gocatamig
DRUG: I-DXd
DRUG: Atezolizumab
DRUG: Carboplatin
DRUG: Etoposide
DRUG: Rescue Medications

Sponsor

Merck Sharp & Dohme LLC

Collaborators

[object Object]